JATT vs. CCCC, JSPR, TNYA, AURA, TRML, MGTX, STRO, AVXL, REPL, and SOPH
Should you be buying JATT Acquisition stock or one of its competitors? The main competitors of JATT Acquisition include C4 Therapeutics (CCCC), Jasper Therapeutics (JSPR), Tenaya Therapeutics (TNYA), Aura Biosciences (AURA), Tourmaline Bio (TRML), MeiraGTx (MGTX), Sutro Biopharma (STRO), Anavex Life Sciences (AVXL), Replimune Group (REPL), and SOPHiA GENETICS (SOPH). These companies are all part of the "biological products, except diagnostic" industry.
JATT Acquisition (NYSE:JATT) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, community ranking, risk and media sentiment.
In the previous week, C4 Therapeutics had 3 more articles in the media than JATT Acquisition. MarketBeat recorded 3 mentions for C4 Therapeutics and 0 mentions for JATT Acquisition. C4 Therapeutics' average media sentiment score of 0.74 beat JATT Acquisition's score of 0.00 indicating that C4 Therapeutics is being referred to more favorably in the news media.
JATT Acquisition has a net margin of 0.00% compared to C4 Therapeutics' net margin of -629.24%. JATT Acquisition's return on equity of -49.58% beat C4 Therapeutics' return on equity.
C4 Therapeutics has a consensus price target of $10.13, indicating a potential upside of 110.06%. Given C4 Therapeutics' higher probable upside, analysts plainly believe C4 Therapeutics is more favorable than JATT Acquisition.
JATT Acquisition has higher earnings, but lower revenue than C4 Therapeutics.
C4 Therapeutics received 25 more outperform votes than JATT Acquisition when rated by MarketBeat users.
48.0% of JATT Acquisition shares are held by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are held by institutional investors. 20.0% of JATT Acquisition shares are held by insiders. Comparatively, 8.0% of C4 Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
C4 Therapeutics beats JATT Acquisition on 7 of the 12 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding JATT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
JATT Acquisition Competitors List
Related Companies and Tools
